1	<b>Cognitive Intervention Effects Vary as a Function of Plasma</b>
2	Neurofilament Light Chain Levels: A PICMOR Randomized
3	Controlled Trial
4	
5	Mihoko Otake-Matsuura <sup>a,*</sup> , Hikaru Sugimoto <sup>a</sup> , Takuya Sekiguchi <sup>a</sup> , Masato S. Abe <sup>a,b</sup> , Kumi
6	W. Miura <sup>a,c</sup> , Seiki Tokunaga <sup>a</sup> , Shoshin Akamine <sup>e</sup> , Taishiro Kishimoto <sup>a,d</sup> , Takashi Kudo <sup>a,e</sup>
7	
8	<sup>a</sup> Center for Advanced Intelligence Project, RIKEN, Tokyo, Japan
9	<sup>b</sup> Faculty of Culture and Information Science, Doshisha University, Kyoto, Japan
10	<sup>c</sup> Japan Society for the Promotion of Science, Tokyo, Japan
11	<sup>d</sup> Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
12	<sup>e</sup> Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan
13	
14	*Correspondence to: Mihoko Otake-Matsuura, PhD, Team Leader, Center for Advanced
15	Intelligence Project, RIKEN, Nihonbashi 1-chome Mitsui Building, 15th floor, 1-4-1
16	Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan. E-mail: mihoko.otake@riken.jp
17	
18	Running title
19	A PICMOR Effect Varies with Plasma NfL Levels

20

### 1 Abstract

Background: There is a difference in the neuronal state of individuals. However, this has
not been taken into consideration in most intervention studies. Recent advances in
analytical technologies in hematological examination enabled us to evaluate neuronal
states in a relatively convenient manner.

Objective: Using these advanced technologies, we aimed to investigate whether cognitive
intervention effects vary as a function of levels of blood-based biomarkers, such as
neurofilament light chain (NfL), since plasma NfL could be a biomarker of
neurodegenerative diseases including Alzheimer's disease.

Methods: In this study, we employed a group conversation-based intervention methodology named Photo-Integrated Conversation Moderated by Robots (PICMOR), which has been shown to improve verbal fluency in older adults. To examine the possibility of varying effects of this intervention method according to the neuronal state of each individual, we conducted a randomized controlled trial (UMIN Clinical Trials Registry number: UMIN000036599) and investigated how longitudinal changes in cognitive performance, such as verbal fluency, vary with the NfL level measured at the baseline.

**Results:** As the main result, positive intervention effects of PICMOR on verbal fluency
were observed in individuals with lower level of NfL, which indicate a relatively intact
neuronal state, whereas negative intervention effects were identified in individuals with
higher NfL level.

Conclusion: Our findings suggest that cognitive intervention effects vary depending on
level of Nfl in the plasma. Thus, future intervention studies should take into account the
neuronal status of the participants to examine intervention effects.

- 1 Keywords: neurofilament light chain, plasma, Alzheimer's disease, PICMOR, verbal
- 2 fluency, conversations

## **1 INTRODUCTION**

2 Dementia is one of the major issues in an aging global population, and its 3 prevention would yield great social benefits. The number of people living with dementia has rapidly increased to 50 million, particularly because of aging populations in low and 4 middle-income countries [1]. Alzheimer's disease (AD) is the most common form of 5 6 dementia, and its pathology progresses for a long time before symptoms appear. AD continuously encompasses several phases: a phase in which pathology is present despite 7 8 cognitive normality [2], a mild cognitive impairment (MCI) phase [3], and, a dementia 9 phase [4]. Since the development of therapeutic agents has not been successful because of the progressive nature of AD, prevention of AD attracts much more attention to delay the 10 progress of pathology or cognitive decline at the normal, preclinical, or MCI phase. Based 11 on the mechanism, cognitively normal older adults are diverse in terms of neuronal state 12 related to AD. Some may have neuronal degeneration, some may be at higher risk of 13 14 neuronal degeneration, and others may not. Therefore, it is possible that there is an individual difference in the degree of the effect of interventions on cognitive functions 15 16 according to the neuronal state of each person.

Previously, the assessment of neuronal state was difficult since the measurement of pathology required positron emission tomography (PET) scanning or collection of cerebrospinal fluid (CSF). Recently, however, cutting-edge analytical technologies in hematological examination have enabled us to estimate neuronal state relatively easily. In this method, the plasma is separated from the blood, and the concentration of neurofilament light chain (NfL), a subunit of neurofilaments, in the plasma is measured, which indicates axonal degeneration. NfL is a neuronal cytoplasmic protein that is highly expressed in

large-caliber myelinated axons [5]. In neurodegenerative diseases, such as AD, the 1 disruption of the axonal membrane causes a sharply increased release of NfL into the 2 interstitial fluid, followed by its release into CSF and blood [6]. Even in normal populations, 3 NfL is constantly released from axons, and the release level is increased with advancing 4 age [7, 8]. Thus, the concentration of this protein in CSF and blood can be considered as 5 6 an indicator of axonal injury. In recent studies, blood-based NfL measurement has been widely adopted because of the following reasons: it is less invasive and more convenient 7 8 relative to the CSF-based method; NfL levels measured by the two methods are correlated 9 [9-12]; and a more sensitive assay, called single-molecule array (Simoa), has been developed [13]. In the present study, we used blood-based method to measure NfL levels 10 and regarded NfL levels as a reliable index of neuronal state, as it has been hypothesized 11 to be a nonspecific marker of neurodegeneration [9-12, 14]. In addition, we employed other 12 blood-based biomarkers as references for comparisons: amyloid- $\beta$  (A $\beta$ ) (A $\beta$ 40 and A $\beta$ 42) 13 14 in extracellular vesicles (EV).

The aim of this study was to examine whether cognitive intervention effects in 15 healthy older adults vary according to their neuronal state. We employed conversational 16 17 interventions to accumulate evidence on the effects of interventions based on social 18 activities, which is still limited in available literature [15]. One of the reasons that social 19 activity-based intervention is scarce is that social activities, such as conversations, occur 20 spontaneously, and it is difficult to regulate their qualities and quantities. To address this issue, we previously developed a cognitive intervention program that utilizes group 21 22 conversations named Photo Integrated Conversation Moderated by Robots (PICMOR) [16]. 23 By using a robot system, controlling the quantity of conversation is enabled. The system

contains two key features: (i) a robot moderator that controls the turn-taking so that all 1 participants speak and listen for the same length of time, and (ii) photos taken by the 2 participants are shown and discussed sequentially with the announcement of a robotic 3 moderator. These features are important for exercising executive functions and episodic 4 memory because the participants have to speak within a designated period of time and have 5 6 to ask and answer questions with flexibility; thus, they would be trained to organize their thoughts and produce them as words. The participants are required to recall their 7 8 autobiographical memories using the photos, and therefore, their ability to recall from 9 memory would be also exercised. Indeed, we previously identified the beneficial effects of the PICMOR program on verbal fluency in older adults [16]. 10

In the present study, we investigated whether the effect of the conversation-based 11 intervention on cognitive functions differs depending on the neuronal state of each 12 participant estimated from blood biomarkers. To do this, we conducted a randomized 13 controlled trial (RCT) on healthy older adults, assuming that the degree to which sub-14 domains of cognitive functions involved in conversations were enhanced by the PICMOR 15 program would vary from individual to individual as a function of the blood levels of NfL. 16 17 More specifically, individuals with lower levels of NfL, which imply a relatively intact 18 neuronal state, would show larger improvement in cognitive performance, such as verbal 19 fluency [16, 17]. This is because the intact neural basis can play its role and enjoy the 20 benefits of cognitive training.

#### 1 METHODS

## 2 Study design and procedure

3 The study was a randomized control trial conducted between May and September 2019 (UMIN Clinical Trials Registry number: UMIN000036599). Figure 1 describes the 4 CONSORT diagram showing an overview of the current study. First, 70 participants were 5 6 assessed for eligibility by medical interview, cognitive tests, and radiologic interpretations. Eighteen participants were excluded under our exclusion criteria and one participant 7 8 withdrew their consent. Therefore, 51 participants were included in the randomization. 9 After baseline assessment, block stratified randomization was performed according to 10 scores of the Japanese version of the Mini-Mental State Examination (MMSE-J) [18] and the Montreal Cognitive Assessment (MoCA-J) [19], and randomly assigned participants to 11 either the intervention (n = 24) or control group (n = 27). We divided participants in the 12 intervention group into six subgroups of four. The intervention group was given 30-minute 13 14 weekly intervention session, followed by 30-minute explanation of the intervention. The control group visited the office weekly as an active control session. During the intervention 15 16 period, two participants were lost to follow-up, with one individual belonging to the 17 intervention group and the other from the control group. Subsequent to the 12-week 18 intervention period, post-assessment was carried out for 49 subjects (intervention: n = 23, 19 control: n = 26). This study was approved by the Institutional Review Board. Written informed consent was obtained from all participants. 20

### 21 **Participants**

The participants were older adults over 65 years in community living who were
enrolled from Silver Human Resources Center, Japan. The exclusion criteria of the current

study were the following: participants with a score of MMSE-J less than 24, neurological impairment, dementia, and any medical condition or medication with a known effect on the central nervous system. Radiological findings assessed by a medical doctor using multiple magnetic resonance imaging (MRI) data, including T1-weighted, T2-weighted, and FLAIR images, were also used as exclusion criteria: cerebral infarctions, meningeal tumors, hemorrhage, or abnormal signals probably caused by metal artifacts.

#### 7 Neuropsychological examination

8 Outcome measurements of cognitive performance in the current study were 9 conducted using MoCA-J, MMSE-J, semantic verbal fluency test [20], subtests of the 10 Wechsler Memory Scale-Revised (WMS-R) [21], including logical memory I and II, 11 subtests of the Wechsler Adult Intelligence Scale- Fourth Edition (WAIS-IV), including 12 the digit symbol coding and digit span forward and backward tests [22], and Trail Making 13 Test (TMT) [23].

MoCA-J and MMSE-J are brief cognitive screening tools composed of multiple domains of cognitive function. In this study, the total score in each test was calculated.

16 Verbal fluency was evaluated by two distinct tests: the phonological verbal (or letter) 17 fluency test from MoCA-J and semantic verbal (or category) fluency test. In the letter fluency test, we instructed to participants to generate as many words as possible in 1 min, 18 with each word being started by the Japanese character 'ka'. In the category fluency test, 19 20 participants were required to speak as many words as they could belonging to the category of animals in 1 min. The two types of verbal fluency tasks differ in whether words are 21 22 generated in a phonologically or semantically driven way. The overall count of words produced was recorded in each test. 23

287976; this version posted March 31, 2023. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2023.03.30.23 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Logical memory I and II are measure of narrative episodic memory that assess both 1 immediate and delayed verbal memory. After reading a brief story, the examiner instructed 2 the participants to reproduce the story's content immediately and again after a duration of 3 30 minutes. Scores were calculated by the sum of the number of elements that were recalled. 4 To avoid learning effects, we used different test stories at the baseline assessment and post-5 6 assessment in this study.

The processing speed and working memory are assessed by the digit symbol coding 7 8 test. In this test, the participants were instructed to transcribe as many of the corresponding 9 symbol as possible, followed by a list of digits. Simple memory span and working memory capacity are measured by the digit span forward and backward tests, respectively. The 10 examiner told the sequence of numbers and required participants to recall the sequence 11 forward and backward. 12

TMT assesses attention and executive function of individuals. In this study, TMT 13 14 was conducted using a PC. In TMT-A, a series of circles, numbered consecutively from 1 to 25, were randomly dispersed throughout the visual display, and the participants were 15 asked to click the cursor on each circle in numerical order. In TMT-B, a series of circles 16 17 included not only numbers ranging from 1 to 13, but also the initial 12 Japanese Hiragana 18 character. We instructed to click on numbers and letters alternatively. The time to perform 19 these tasks was recorded.

20

# Blood sampling and separation of plasma

Blood was collected in EDTA tubes in the Advanced Imaging Center (AIC) Yaesu 21 22 Clinic, Tokyo, Japan. The blood was centrifuged at 2,500 g for 15 min at room temperature, 18 °C, within 24 h after sampling, and stored at -80 °C for future analyses and transported 23

to Osaka University. The following procedures, isolation of neuron-derived extracellular
vesicles (EV) (NDE) fraction from plasma, measurements of Aβ40, Aβ42 in plasmaderived NDE fraction, and measurements of serum NfL were conducted at Osaka
University, Osaka, Japan.

We measured Plasma NfL concentration twice with the Simoa platform, using Simoa
NF-Light Advantage kits on a Simoa HD-1 Analyzer instrument (Quanterix Corporation)
[24]. We set 0.466 pg/mL as the lower limit for NfL concentration. We excluded samples
with either fatal measurement errors or coefficients of variance (CV) > 20 %. In all batches,
we measured two types of quality-control samples provided in the kit twice, in order to
ensure measurement validity. The mean CV of duplicates was 4.4 %.

#### 12 Isolation of NDE fraction from plasma

NDE fractions were isolated from plasma using the previous method reported by 13 Goetzl and Kapogiannis group [25-27] with some modifications. 7.5 µL thrombin 14 (Thrombin Plasma prep #TMEXO-1; System Bioscience, CA, USA) was added to 250 µL 15 16 plasma and incubated for 30 min at room temperature to remove fibrin by clot formation. After the addition of 242.5 µL of Dulbecco's phosphate-buffered saline with no calcium 17 and magnesium ion (D-PBS(-)) (#14249-95; Nacalai Tesque, Kyoto, Japan), tubes were 18 gently mixed by inverting three times, and centrifuged at 4,000 g for 20 min at 4 °C. 19 20 Supernatants were transferred to fresh tubes and added 126 µL of ExoQuick solution (#EXOQ5A-1; System Bioscience, CA, USA), and gently mixed by inverting three times. 21 Tubes were incubated for 60 min at 4 °C and centrifuged at 1,500 g for 20 min at 4 °C. 22

<sup>5</sup> Measurements of serum NfL

1	Supernatants were discarded after centrifugation, and the pellet was resuspended in 250 $\mu L$
2	of deionized water. The solution was incubated overnight at 4 °C with rotation for complete
3	resuspension. To isolate NDE fraction from total plasma-EVs, 2 µg of biotinylated anti-
4	L1CAM antibody (#13-1719-82; eBioscience, CA, USA) in 21 $\mu$ L of 3 % bovine serum
5	albumin (BSA) (Blocker BSA, #37525; Thermo Fisher Scientific, MA, USA) diluted with
6	D-PBS(-) was added and incubated for 60 min at 4 °C with rotation, followed by addition
7	of 7.5 µL of streptavidin-agarose resin (Pierce Streptavidin Plus UltraLink Resin, #53116;
8	Thermo Fisher Scientific, MA, USA) and 12.5 $\mu L$ of 3 % BSA. The solution was further
9	incubated for 30 min at 4 °C with rotation, centrifuged at 200 g for 10 min at 4 °C, then the
10	supernatant was carefully removed. NDE fraction was eluted by 100 $\mu$ L of 0.1 M glycine-
11	HCl (pH 3.0), the resin was removed by centrifugation at 4,500 g for 10 min at 4 °C,
12	followed by neutralization with 7.5 $\mu L$ of 1 M Tris-HCl (pH 8.0) and 7.5 $\mu L$ of 10 % BSA.
13	EVs were lysed by adding 135 $\mu L$ of M-PER (#78501; Thermo Fisher Scientific, MA,
14	USA) and two freeze-thaw cycles.

All D-PBS(-), deionized water, and M-PER were supplemented with protease 15 inhibitor cocktail (cOmplete Protease Inhibitor Cocktail, #04693116001; Sigma-Aldrich, 16 17 MO, USA) and phosphatase inhibitor cocktail (PhosSTOP, #4906847001; Sigma-Aldrich, 18 MO, USA) to three times the concentration recommended by the manufacturer, before use.

#### Measurements of A\$40, A\$42 in plasma-derived NDE fraction 19

We measured Plasma-derived NDE A $\beta$ 40/A $\beta$ 42 concentration twice with the 20 ultrasensitive Simoa platform, using Simoa Neurology 3-Plex A Advantage kits on a Simoa 21 HD-1 Analyzer instrument (Quanterix Corporation) [24]. We diluted samples 4-fold with 22 sample diluent reagent in the instrument during measurement. The lower limit of 23

quantification for Aβ40 and was 0.675 pg/mL and that of Aβ42 was and 0.142 pg/mL. We
 excluded samples with either fatal measurement errors or CV > 20 % from the analysis. In
 all batches, we measured two types of quality-control samples provided in the kit twice, in
 order to ensure measurement validity. The mean CV of duplicates was 4.4 % and 3.5 %,
 respectively.

6

### 7 MRI data acquisition and preprocessing

8 Anatomical brain structures were scanned using a high-resolution T1-weighted 9 image. The scan parameters were as follows: repetition time = 6.41 ms, echo time = 3.00ms, field of view = 24.0 cm  $\times$  24.0 cm, matrix size = 256  $\times$  256, slice thickness/gap = 1.2/0 10 mm, and 170 sagittal slices. The participant's head was fixed with a belt and foam pads 11 12 during the scan. Resting-state functional images and diffusion tensor images were also collected and used for other purposes. All MRI data were acquired using a Philips Achieva 13 3T MRI scanner at the AIC Yaesu Clinic. The T1-weighted images were preprocessed 14 using Statistical Parametric Mapping (SPM) 12. The images were segmented into 15 16 intracranial parts of gray matter (GM), white matter (WM), CSF, and other non-brain 17 structures using the standard unified segmentation module [28]. From the segmented images, individual GM, WM, and CSF volumes were calculated for analysis. Total brain 18 volumes (TBVs) and total intracranial volumes (TIVs) were defined as the sum of GM and 19 20 WM and the sum of the three parts (GM + WM + CSF), respectively.

287976; this version posted March 31, 2023. The copyright holder for this preprint medRxiv preprint doi: https://doi.org/10.1101/2023.03.30.2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

#### *Covariates* 1

2 Age, sex, educational level, family structure, competency, depressive tendency, and quality of life were assessed as covariates. Competency was assessed by the Tokyo 3 Metropolitan Institute of Gerontology-Index of Competence (TMIG-IC) [29], and the 4 subject's depressive tendency was evaluated by the Geriatric Depression Scale short form 5 6 (GDS-15) [30]. World Health Organization quality of life questionnaire 26 was used to 7 evaluate the quality of life of the participants [31].

#### 8 Statistical analysis: Intervention effects

9 To estimate the intervention effect, we performed the linear mixed models with random intercepts for outcome measures (scores of cognitive tests, brain volumes, and 10 11 levels of blood biomarkers) by using the R package 'lme4' [32]. The models included the 12 group assignment factor (the intervention group was coded as 1 and the control group was coded as 0), the time factor (pre-experiment was coded as 1 and post-experiment was coded 13 as 0), and their interaction term as independent variables. We reported the interaction term 14 15 as the intervention effect.

## 16

# Statistical analysis: Intervention effects depending on levels of blood biomarkers

To observe at which biomarker level the time effect and the intervention effect on 17 18 cognitive test scores conditional on the biomarker level were significant, we constructed 19 the linear mixed models with random-intercepts, which included the group factor, the time 20 factor, the biomarker levels, and all the possible interaction terms. We then applied the simple slope analysis to those models, in which we subtracted specific values from the raw 21 22 values of biomarker levels and then conducted the same models again.

1 We reported ranges of biomarker levels where the time effects within the 2 intervention and control groups and the intervention effect on the outcomes were 3 significant at levels of 0.05.

#### 4 **RESULTS**

### 5 **Baseline characteristics of participants**

6 Table 1 compares the baseline characteristics of study participants in the 7 intervention and control groups.

8

## Intervention effects in cognitive test scores, brain volumes, and blood biomarkers

9 Table S3 compares the cognitive test scores and brain volumes measured at pre-10 and post-experiment between the intervention and control groups. No statistically 11 significant intervention effects were observed for any of the scores and brain volumes.

Table S4 compares the levels of blood biomarkers pre- and post-experiment between the intervention and control groups. There were no significant intervention effects observed on levels of any biomarkers.

#### 15 Intervention effects depending on levels of blood biomarkers

For lower (higher) levels of NfL, a significantly positive (negative) intervention
effect on category fluency was observed (Fig. 2).

For a higher level of NfL, significantly negative intervention effects on logical memories I and II were observed (Fig. S1A and B), and for a level of NfL close to the median, a significantly negative intervention effect on Digit span backward was observed (Fig. S1C).

- For a lower (higher) level of Aβ40, a significantly positive (negative) intervention
   effect on digit span forward was observed (Fig. S1D).
- For a level of Aβ40 close to the median, a significantly negative intervention effect
  on digit span backward was observed (Fig. S1E). For a higher level of Aβ42, a significantly
  negative intervention effect on the volume of white matter was observed (Fig. S1F).
- Figure S2 shows that the time effects on cognitive test scores within the intervention
  and control groups were not negative. By contrast, the time effects on brain volumes were
  negative in many cases.

#### 9 **DISCUSSION**

In this study, we examined whether cognitive intervention effects vary as a function of levels of blood-based biomarkers, assuming that individuals with lower levels of NfL would show a larger enhancement in verbal fluency. Although we did not find significant intervention effects in any task scores when the blood-based biomarkers were not taken into consideration, we successfully identified differential intervention effects on performance in one of two verbal fluency tasks when individuals were categorized by the level of NfL.

Our previous RCT employed a letter fluency task and identified a significant intervention effect of PICMOR on this task score [16], whereas the present RCT used a category fluency task as well as the letter one and found no significant intervention effects on both task scores (see Table S3). This difference could be explained by a difference in the baseline level of task performance between the previous and present RCT participants. In this study, both the intervention and control groups scored 14 on average in the letter fluency test, which are significantly higher than the previous participants who scored 11

on average [16]. Considering that normative data regarding this task performance show 1 that people aged 60 and 70 years score 7 on average [33], the baseline level of participants 2 3 in this study is extremely high, and hence it is possible that there was a smaller room for growth in the task performance compared to the previous RCT participants. Similarly, the 4 current participants scored 17 on average at baseline in the category fluency test, which is 5 6 extremely higher than normative data of people aged 60 and 70 years scoring the 14 and 11 on average, respectively [33]. Nevertheless, when considering NfL levels, we found a 7 8 significantly positive intervention effect in the semantic verbal fluency task for individuals 9 with lower levels of NfL (see Fig. 1A). In contrast, no significant effects were observed in the phonological one, even when the NfL was taken into consideration. This difference 10 may be reasonable because the phonological one is more difficult to perform than the 11 semantic one [33]. The present findings suggest that even in populations with high level 12 performance, there is an individual difference in the neuronal state and cognitive 13 14 intervention effects are prominent for individuals with a relatively intact neuronal status. On the other hand, a negative intervention effect was observed in those who had higher 15 levels of NfL. Thus, the finding of no significant intervention effects on verbal fluency 16 17 unless NfL levels are not taken into account could be also explained by the possibility that 18 the effects were counterbalanced between individuals with lower and higher NfL levels. 19 Taken together, our findings suggest that cognitive intervention effects vary as a function 20 of NfL levels.

This study showed an advantage of using plasma NfL levels in intervention studies. Recently, there has been a growing interest in blood-based NfL as a biomarker of neurodegenerative diseases [9-12, 14]. In addition, several studies have attempted to use it

as a measure of treatment for diseases [9]. In aging research, the NfL levels have been 1 shown to increase with normal aging [7, 8]. This index has also been used in cohort and 2 RCT studies for healthy older adults [34, 35]. For example, Desai et al. (2022) utilized the 3 NfL levels to classify the participants and investigated the association between physical 4 activity levels and cognitive decline [34]. Our study proposed a new usage of the NfL by 5 6 employing it for the classification of participants to examine a cognitive intervention effect among healthy older populations. This is informative for other intervention studies because 7 8 the effects of any intervention methods vary as a function of NfL levels. In contrast, we 9 could not identify a similar pattern when using  $A\beta$  levels for classification. This is presumably because the measurement may not reflect only AB levels measured from 10 neuron-derived exosomes. We originally used L1CAM as a marker of brain neuronal EV 11 and collected exosomes with L1CAM to measure A $\beta$  levels in neural cells. However, the 12 utility of L1CAM as a marker of brain neuronal EVs has been questioned recently because 13 14 some of L1CAM is expressed in other organs, such as the kidneys, and most of L1CAM in the blood is truncated, lacking the transmembrane region which anchors L1CAM to the 15 membrane of EVs [36-38]. Thus, it is important to develop a new technology to distinguish 16 17 neuron-derived exosomes from those that came out of other organs. Taken together, the 18 plasma NfL measured in this study could be considered as purely reflecting neuronal state. 19 In this study, significant negative intervention effects were observed on logical 20 memory task scores (I and II) (Fig. S1) as well as the categorical verbal fluency task score among participants with higher levels of NfL (see Fig. 2). In addition, participants with 21 22 middle levels of NfL showed significant negative intervention effects in the digit span 23 backward test (see Fig. S1). These findings suggest that individuals with high or medium

levels of NfL do not benefit from cognitive intervention due a relatively vulnerable neural 1 basis. From the results, we can at least derive a practical implication that an appropriate 2 3 intervention program should be designed according to the levels of biomarkers. Future research needs to investigate how strong the intervention strength should be to improve 4 their cognitive performance by changing the frequency or duration of interventions or the 5 6 cognitive load demanded in interventions. A cohort study reported that even in individuals with higher levels of NfL, those who have high or medium levels of physical activity 7 8 showed reduced cognitive decline relative to those who have low physical activity levels 9 [34]. Considering that the PICMOR method has various variables that can be changed, such as the number of topics to be provided, it may be effective to increase the cognitive 10 demands during the intervention as well as to increase the frequency or duration of 11 interventions for individuals with lower levels of NfL. 12

The PICMOR-based conversation is designed to train cognitive functions, such as 13 14 executive functions and episodic memory [16]. In this structured group conversation, participants were required to make a presentation on recently encountered events within a 15 limited time, ask and answer questions among group members, and refrain from making a 16 17 comment when other members were talking. To provide topics, they had to recall their 18 autobiographical memory and explain it in a concise manner. To ask questions, they had to 19 temporarily retain information in working memory and understand what others meant and 20 what was unclear with reference to one's knowledge. As expected, our series of RCTs provided consistent evidence that the verbal fluency ability, which is based on executive 21 22 control and verbal abilities [39], can be improved by engaging in the PICMOR-based 23 conversation. However, it remains unclear what components in this structured conversation

are responsible for the enhancement of verbal fluency [40]. Further research is needed to
address this issue by investigating whether repeated training specialized in each component
of conversations, such as asking questions, results in the improvement of cognitive abilities.
Furthermore, considering the pandemic of COVID-19, it is important to develop more
easily available methods for people in isolation or those who cannot go out, which do not
require an on-site conversation, such as tablet-based or application-based conversations.

In conclusion, we found that cognitive intervention effects vary as a function of levels of blood-based biomarkers. Importantly, we demonstrated that the beneficial effects of our recently developed intervention program on verbal fluency are prominent in individuals with lower levels of NfL. From these findings, we can suggest for future intervention studies that it is important to estimate the neuronal state of participants when determining the effectiveness of intervention methodologies.

### 13 ACKNOWLEDGMENTS

We thank the staff of the AIC Yaesu Clinic for their technical assistance in the MRI
scanning and blood sampling. This work was supported by JSPS KAKENHI (Grant
Numbers: JP18KT0035, JP19H01138, JP19K14489, JP20H05022, JP20H05574,
JP20K19471, JP22H04872, JP22H00544) and the Japan Science and Technology Agency
(Grant Numbers: JPMJCR20G1, JPMJPF2101, and JPMJMS2237).

19 Conflict of Interest/Disclosure Statement

20 The authors have no conflict of interest to report.

#### REFERENCES

22

21 [1] Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al.

(2017) Dementia prevention, intervention, and care. Lancet **390**, 2673-2734.

1	[2]	Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo
2		T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E,
3		Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV,
4		Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease:
5		Recommendations from the National Institute on Aging-Alzheimer's Association
6		workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement
7		7, 280-292.
8	[3]	Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A,
9		Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps
10		CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's
11		disease: recommendations from the National Institute on Aging-Alzheimer's
12		Association workgroups on diagnostic guidelines for Alzheimer's disease.
13		Alzheimers Dement 7, 270-279.
14	[4]	McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH,
15		Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor
16		MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The
17		diagnosis of dementia due to Alzheimer's disease: Recommendations from the
18		National Institute on Aging-Alzheimer's Association workgroups on diagnostic
19		guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
20	[5]	Zetterberg H (2016) Neurofilament light: A dynamic cross-disease fluid
21		biomarker for neurodegeneration. Neuron 91, 1-3.
22	[6]	Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, Bestwick
23		JP, Monsch AU, Regeniter A, Lindberg RL, Kappos L, Leppert D, Petzold A,

1		Giovannoni G, Kuhle J (2013) Increased neurofilament light chain blood levels in
2		neurodegenerative neurological diseases. PLoS One 8, e75091.
3	[7]	Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, Benkert P,
4		Ropele S, Enzinger C, Fazekas F, Schmidt R, Kuhle J (2020) Serum
5		neurofilament light levels in normal aging and their association with morphologic
6		brain changes. Nat Commun 11, 812.
7	[8]	Ladang A, Kovacs S, Lengele L, Locquet M, Reginster JY, Bruyere O, Cavalier E
8		(2022) Neurofilament light chain concentration in an aging population. Aging Clin
9		<i>Exp Res</i> <b>34</b> , 331-339.
10	[9]	Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019)
11		Neurofilament light chain as a biomarker in neurological disorders. J Neurol
12		Neurosurg Psychiatry 90, 870-881.
13	[10]	Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C,
14		Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle
15		J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol
16		14, 577-589.
17	[11]	Wang SY, Chen W, Xu W, Li JQ, Hou XH, Ou YN, Yu JT, Tan L (2019)
18		Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for
19		neurodegenerative diseases: A systematic review and meta-analysis. J Alzheimers
20		Dis 72, 1353-1361.
21	[12]	Xiong YL, Meng T, Luo J, Zhang H (2021) The potential of neurofilament light
22		as a biomarker in Alzheimer's disease. Eur Neurol 84, 6-15.

1	[13]	Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A, Liman V,
2		Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical
3		platforms for quantification of the neurofilament light chain in blood samples:
4		ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med
5		<b>54</b> , 1655-1661.
6	[14]	Zhao Y, Xin Y, Meng S, He Z, Hu W (2019) Neurofilament light chain protein in
7		neurodegenerative dementia: A systematic review and network meta-analysis.
8		Neurosci Biobehav Rev 102, 123-138.
9	[15]	World Health Organization (2019) Risk reduction of cognitive decline and
10		dementia: WHO guidelines,
11		https://www.who.int/publications/i/item/9789241550543.
12	[16]	Otake-Matsuura M, Tokunaga S, Watanabe K, Abe MS, Sekiguchi T, Sugimoto
13		H, Kishimoto T, Kudo T (2021) Cognitive intervention through Photo-Integrated
14		Conversation Moderated by Robots (PICMOR) program: A randomized
15		controlled trial. Front Robot AI 8, 633076.
16	[17]	Dodge HH, Zhu J, Mattek N, Bowman M, Ybarra O, Wild K, Loewenstein DA,
17		Kaye JA (2015) Web-enabled conversational interactions as a means to improve
18		cognitive functions: Results of a 6-week randomized controlled trial. Alzheimers
19		Dement (N Y) 1, 1-12.
20	[18]	Sugishita M, Koshizuka Y, Sudou S, Sugishita K, Hemmi I, Karasawa H, Ihara
21		M, Takashi A, Mihara B (2018) The validity and reliability of the Japanese
22		version of the Mini-Mental State Examination (MMSE-J) with the original

1		procedure of the Attention and Calculation Task (2001). Japanese J Cogn
2		<i>Neurosci</i> <b>20</b> , 91-110.
3	[19]	Fujiwara Y, Suzuki H, Yasunaga M, Sugiyama M, Ijuin M, Sakuma N, Inagaki H,
4		Iwasa H, Ura C, Yatomi N, Ishii K, Tokumaru AM, Homma A, Nasreddine Z,
5		Shinkai S (2010) Brief screening tool for mild cognitive impairment in older
6		Japanese: validation of the Japanese version of the Montreal Cognitive
7		Assessment. Geriatr Gerontol Int 10, 225-232.
8	[20]	Lezak MD, Howieson DB, Bigler ED, Tranel D (2012) Neuropsychological
9		Assessment, Oxford University Press, New York.
10	[21]	Wechsler D (1987) Wechsler Memory Scale-Revised, Pearson, San Antonio.
11	[22]	Wechsler D (2008) Wechsler Adult Intelligence Scale—Fourth Edition, Pearson,
12		San Antonio.
13	[23]	Mizuno K, Watanabe Y (2008) Utility of an advanced trail making test as a
14		neuropsychological tool for an objective evaluation of work efficiency during
15		mental fatigue In Fatigue Science for Human Health, Watanabe Y, Evengård B,
16		Natelson BH, Jason LA, Kuratsune H, eds. Springer, Tokyo, pp. 47-54.
17	[24]	Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K,
18		Sakagami Y, Mori K, Adachi H, Kozawa J, Maeda N, Otsuki M, Matsuoka T,
19		Iwahashi H, Shimomura I, Ikeda M, Kudo T (2020) Renal function is associated
20		with blood neurofilament light chain level in older adults. Sci Rep. 10(1), 20350.
21	[25]	Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB,
22		Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ (2015) Identification
23		of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally

1		derived blood exosomes: A case-control study. Alzheimers Dement 11, 600-607
2		e601.
3	[26]	Guix FX, Corbett GT, Cha DJ, Mustapic M, Liu W, Mengel D, Chen Z, Aikawa
4		E, Young-Pearse T, Kapogiannis D, Selkoe DJ, Walsh DM (2018) Detection of
5		aggregation-competent tau in neuron-derived extracellular vesicles. Int J Mol Sci
6		19.
7	[27]	Mustapic M, Eitan E, Werner JK, Jr., Berkowitz ST, Lazaropoulos MP, Tran J,
8		Goetzl EJ, Kapogiannis D (2017) Plasma extracellular vesicles enriched for
9		neuronal origin: A potential window into brain pathologic processes. Front
10		Neurosci 11, 278.
11	[28]	Ashburner J, Friston KJ (2005) Unified segmentation. Neuroimage 26, 839-851.
12	[29]	Koyano W, Shibata H, Nakazato K, Haga H, Suyama Y (1991) Measurement of
13		competence: reliability and validity of the TMIG Index of Competence. Arch
14		<i>Gerontol Geriatr</i> <b>13</b> , 103-116.
15	[30]	Sugishita K, Sugishita M, Hemmi I, Asada T, Tanigawa T (2017) A validity and
16		reliability study of the Japanese version of the Geriatric Depression Scale 15
17		(GDS-15-J). Clin Gerontol 40, 233-240.
18	[31]	Tazaki M, Nakane Y (1997) WHO QOL26 Japanese version manual, Kaneko
19		Shobo, Tokyo.
20	[32]	Bates D, Mächler M, Bolker B, Walker S (2015) Fitting linear mixed-effects
21		models using lme4. J Stat Softw 67, 1-48.

1	[33]	Ito E, Hatta T, Ito Y, Kogure T, Watanabe H (2004) Performance of verbal
2		fluency tasks in Japanese healthy adults: Effect of gender, age and education on
3		the performance. Japanese J Neuropsychology 20, 254-263.
4	[34]	Desai P, Dhana K, DeCarli C, Wilson RS, McAninch EA, Evans DA, Rajan KB
5		(2022) Examination of neurofilament light chain serum concentrations, physical
6		activity, and cognitive decline in older adults. JAMA Netw Open 5, e223596.
7	[35]	He L, de Souto Barreto P, Aggarwal G, Nguyen AD, Morley JE, Li Y, Bateman
8		RJ, Vellas B, Group MD (2020) Plasma Abeta and neurofilament light chain are
9		associated with cognitive and physical function decline in non-dementia older
10		adults. Alzheimers Res Ther 12, 128.
11	[36]	Gomes DE, Witwer KW (2022) L1CAM-associated extracellular vesicles: A
12		systematic review of nomenclature, sources, separation, and characterization. $J$
13		Extracell Biol 1.
14	[37]	Hill AF (2019) Extracellular vesicles and neurodegenerative diseases. J Neurosci
15		<b>39</b> , 9269-9273.
16	[38]	Norman M, Ter-Ovanesyan D, Trieu W, Lazarovits R, Kowal EJK, Lee JH, Chen-
17		Plotkin AS, Regev A, Church GM, Walt DR (2021) L1CAM is not associated
18		with extracellular vesicles in human cerebrospinal fluid or plasma. Nat Methods
19		<b>18</b> , 631-634.
20	[39]	Shao Z, Janse E, Visser K, Meyer AS (2014) What do verbal fluency tasks
21		measure? Predictors of verbal fluency performance in older adults. Front Psychol
22		5, 772.

- 1 [40] Sugimoto H, Kawagoe T, Otake-Matsuura M (2020) Characteristics of resting-
- 2 state functional connectivity in older adults after the PICMOR intervention
- 3 program: A preliminary report. *BMC Geriatr* **20**, 486.

# **Figures and Tables**



# Fig. 1. The CONSORT diagram of the current study



Fig. 2. The intervention effects on the scores of category fluency tests for varying levels of NfL. The black thick line indicates the estimated intervention effect, and the black thin lines indicate the upper and lower bounds of the associated 95 % confidence interval. On the horizontal line at y = 0, the red region shows the region of the biomarker level in which the intervention effect was positively significant at the 5 % level, and the blue region shows the region of the biomarker level in which the intervention effect was negatively significant at the 5 % level. The gray region shows the region of non-significance for the intervention effect. The range of the horizontal axis is truncated to the observed ranges. The vertical dashed green line indicates the median of the observed level of the biomarker.

	Intervention	Control
	( <i>n</i> = 23)	( <i>n</i> = 26)
Age (Mean ± SD)	$72.30\pm4.15$	$72.04 \pm 4.05$
Gender (Female; <i>n</i> , %)	13 (56.5 %)	17 (65.4 %)
Education ( $\geq$ 13 years; <i>n</i> , %)	16 (69.6 %)	21 (80.8 %)
MMSE (Mean ± SD)	$28.17 \pm 1.75$	$28.19 \pm 1.70$
GDS-15 (Mean ± SD)	$1.57 \pm 1.65$	$2.65\pm3.07$
TMIG-IC		
Total score (Mean ± SD)	$12.2\pm0.96$	$11.88 \pm 1.53$
Instrumental activity of daily living (Mean $\pm$ SD)	$4.83\pm0.49$	$4.88\pm0.33$
Intellectual activity (Mean ± SD)	$3.74 \pm 0.54$	$3.62\pm0.64$
Social role (Mean ± SD)	$3.70\pm0.47$	$3.38\pm0.90$

# Table 1. Baseline characteristic between intervention and control group



Fig. S1 The intervention effects on the scores of the cognitive tests and brain volumes for varying levels of biomarkers. The black thick line indicates the estimated intervention effect, and the black thin lines indicate the upper and lower bounds of the associated 95 % confidence interval. On the horizontal line at y = 0, the red region shows the region of the biomarker level in which the intervention effect was positively significant at the 5 % level, and the blue region shows the region of the biomarker level in which the intervention effect was negatively significant at the 5 % level. The gray region shows the region of non-significance for the intervention effect. The range of the horizontal axis is truncated to the observed ranges. The vertical dashed green line indicates the median of the observed level of the biomarker.



Fig. S2. The time effects on the scores of the cognitive tests and brain volumes for varying levels of biomarkers. (A-C) show the results within the intervention group, and (D-F) show those within the control group. On each horizontal bar, the red (blue) region shows the region of the biomarker level in which the time effect was positively (negatively) significant at the 5 % level. Gray region shows the region of nonsignificance for the time effect. The range of the horizontal axis is truncated to the observed ranges. The vertical dashed green line indicates the median of the observed level of the biomarker.

	Interv	rention	Cor	ntrol		Estimates	
	Pre Mean (SD)	Post Mean (SD)	Pre Mean (SD)	Post Mean (SD)	Time $(SE, p)$	Group (SE, <i>p</i> )	Time $\times$ Group (SE, $p$ )
Cognitive test scores	5						
MMSE-J	28.174	28.261	28.192	28.308	0.115	-0.018	-0.028
	(1.749)	(1.322)	(1.698)	(1.408)	(0.284, 0.686)	(0.445, 0.967)	(0.414, 0.946)
MoCA-J	25.087	26.391	24.654	25.885	1.231	0.433	0.074
	(2.745)	(2.231)	(3.261)	(3.051)	(0.526, 0.024)	(0.821, 0.600)	(0.767, 0.924)
Category fluency	17.478	18.043	17.846	17.115	-0.731	-0.368	1.296
	(3.764)	(5.555)	(4.730)	(4.412)	(0.797, 0.364)	(1.332, 0.783)	(1.164, 0.271)
Letter fluency	14.130	14.478	14.808	14.462	-0.346	-0.677	0.694
	(4.159)	(5.846)	(3.555)	(3.765)	(0.642, 0.592)	(1.254, 0.591)	(0.937, 0.462)
Logical memory I	10.000	11.696	10.346	12.346	2.000	-0.346	-0.304
(immediate)	(4.852)	(3.971)	(4.039)	(4.354)	(0.888, 0.029)	(1.234, 0.780)	(1.296, 0.815)
Logical memory II	7.826	9.696	9.500	11.423	1.923	-1.674	-0.054
(delayed)	(4.783)	(4.028)	(4.150)	(5.085)	(0.927, 0.044)	(1.299, 0.202)	(1.353, 0.969)
Symbol	67.130	68.000	68.115	69.000	0.885	-0.985	-0.015
	(14.169)	(15.886)	(13.840)	(13.291)	(1.181, 0.457)	(4.088, 0.811)	(1.723, 0.993)
Digit span forward	9.478	10.391	9.846	10.269	0.423	-0.368	0.490
	(1.855)	(3.461)	(2.738)	(2.808)	(0.523, 0.423)	(0.794, 0.645)	(0.763, 0.524)
Digit span	7.739	7.870	7.577	8.731	1.154	0.162	-1.023
backward	(2.179)	(1.984)	(1.748)	(2.409)	(0.364, 0.003)	(0.600, 0.788)	(0.531, 0.060)
TMT-A	4.402	4.497	4.267	4.213	-0.054	0.135	0.149
	(0.514)	(0.538)	(0.504)	(0.287)	(0.089, 0.550)	(0.134, 0.317)	(0.130, 0.259)
ТМТ-В	4.881	4.856	4.745	4.740	-0.004	0.137	-0.021
	(0.595)	(0.602)	(0.559)	(0.523)	(0.101, 0.966)	(0.163, 0.404)	(0.148, 0.886)
Brain volumes ( <i>l</i> )							
GM	0.567	0.561	0.560	0.556	-0.004	0.007	-0.002
	(0.048)	(0.049)	(0.051)	(0.048)	(0.002, 0.079)	(0.014, 0.599)	(0.003, 0.412)
WM	0.393 (0.043)	0.392 (0.045)	0.391 (0.036)	0.389 (0.035)	-0.002 (0.001, 0.037)	0.002 (0.011, 0.834)	0.001 (0.002, 0.726)

# Table S3. Comparison of cognitive test scores and brain volumes at pre- and postexperiments between the intervention and control groups

CSF	0.475	0.478	0.453	0.452	-0.001	0.022	0.003
	(0.075)	(0.073)	(0.074)	(0.074)	(0.002, 0.728)	(0.021, 0.296)	(0.003, 0.325)
TBV	0.961	0.953	0.951	0.945	-0.006	0.010	-0.002
	(0.077)	(0.078)	(0.078)	(0.074)	(0.002, 0.001)	(0.022, 0.658)	(0.003, 0.474)
TIV	1.436	1.431	1.404	1.397	-0.007	0.032	0.002
	(0.129)	(0.127)	(0.120)	(0.122)	(0.001, 0.000)	(0.036, 0.370)	(0.002, 0.369)

Note. Scores of TMT-A and -B were logarithmic transformed.

	Interv	Intervention		ntrol	Estimates			
	Pre Mean (SD)	Post Mean (SD)	Pre Mean (SD)	Post Mean (SD)	Time (SE, <i>p</i> )	Group (SE, <i>p</i> )	Time $\times$ Group (SE, $p$ )	
NfL	13.384	16.131	16.312	18.346	2.034	-2.928	0.714	
	(3.705)	(5.473)	(6.231)	(4.824)	(0.729, 0.008)	(1.480, 0.052)	(1.064, 0.506)	
Αβ40	11.607	11.059	10.760	38.976	28.215	0.847	-28.764	
	(9.379)	(6.599)	(6.275)	(102.496)	(14.534, 0.058)	(14.194, 0.953)	(20.851, 0.174)	
Αβ42	27.544 (29.835)	20.950 (20.180 )	28.323 (30.963)	17.917 (25.217)	-10.781 (6.533, 0.106)	-0.779 (7.745, 0.920)	3.986 (9.477, 0.676)	
log(NfL)	2.556	2.734	2.732	2.876	0.143	-0.176	0.035	
	(0.284)	(0.306)	(0.341)	(0.268)	(0.035, 0.000)	(0.086, 0.046)	(0.051, 0.500)	
log(Aβ40)	2.199	2.208	2.221	2.143	-0.084	-0.023	0.088	
	(0.719)	(0.689)	(0.564)	(1.485)	(0.247, 0.735)	(0.262, 0.931)	(0.354, 0.806)	
$\log(A\beta 42)$	2.949	2.702	2.908	2.271	-0.651	0.042	0.395	
	(0.780)	(0.837)	(0.896)	(1.156)	(0.202, 0.002)	(0.266, 0.876)	(0.293, 0.185)	

### Table S4. Comparison of levels of biomarkers at pre- and post-experiment between the intervention and control groups

*Note.* For A $\beta$ 40, two participants and five ones were excluded from the intervention and control groups at the endpoint due to lower levels than the lower limit of the measurable range. For A $\beta$ 42, one participant was excluded from the intervention group at the endpoint due to the level lower than the measurable range, and one participant and another participant in the control group were excluded due to levels lower and higher than the measurable range.